医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

nivolumab

Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: CheckMate ipilimumab Long-Term Survival with Opdivo nivolumab Six-Year Outcomes

2023年09月11日

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: cabozantinib Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX nivolumab OPDIVO

2021年08月26日

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: cabozantinib Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX nivolumab OPDIVO

2020年10月27日

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: cabozantinib Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX nivolumab OPDIVO

2020年10月27日

Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer

Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Labor and Welfare Approves Opdivo nivolumab

2020年02月21日